MYNZ Stock Overview
Develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Mainz Biomed N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.23 |
| 52 Week High | US$1.79 |
| 52 Week Low | US$0.19 |
| Beta | 0.076 |
| 11 Month Change | -13.13% |
| 3 Month Change | -36.39% |
| 1 Year Change | -79.55% |
| 33 Year Change | -97.69% |
| 5 Year Change | n/a |
| Change since IPO | -97.75% |
Recent News & Updates
Shareholder Returns
| MYNZ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.5% | 4.0% | 2.2% |
| 1Y | -79.5% | 18.3% | 32.6% |
Return vs Industry: MYNZ underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: MYNZ underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| MYNZ volatility | |
|---|---|
| MYNZ Average Weekly Movement | 19.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MYNZ's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MYNZ's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 68 | Guido Baechler | mainzbiomed.com |
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Mainz Biomed N.V. Fundamentals Summary
| MYNZ fundamental statistics | |
|---|---|
| Market cap | US$5.29m |
| Earnings (TTM) | -US$22.51m |
| Revenue (TTM) | US$917.20k |
6.3x
P/S Ratio-0.3x
P/E RatioIs MYNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYNZ income statement (TTM) | |
|---|---|
| Revenue | US$917.20k |
| Cost of Revenue | US$376.25k |
| Gross Profit | US$540.96k |
| Other Expenses | US$23.05m |
| Earnings | -US$22.51m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 58.98% |
| Net Profit Margin | -2,453.86% |
| Debt/Equity Ratio | -166.8% |
How did MYNZ perform over the long term?
See historical performance and comparison